Peter Kolchinsky - 29 Jun 2021 Form 4 Insider Report for Therapeutics Acquisition Corp.

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: N/A
Reported as of: 29 Jun 2021
Net transaction value: +$2,091,000
SEC form: 4
Accepted by SEC: 30 Jun 2021, 16:31:24 UTC
Prior SEC filing: 24 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Matthew Hammond as Attorney-in-Fact

Key filing fact

Peter Kolchinsky filed Form 4 for Therapeutics Acquisition Corp. on 30 Jun 2021.

Key facts

This page summarizes Peter Kolchinsky's Form 4 filing for Therapeutics Acquisition Corp..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Jun 2021, 16:31.

Change

Previous filing in this sequence was filed on 24 Jun 2021.
Current net transaction value: +$2,091,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PNT transaction

Common Stock

Award

Transaction value: $2,091,000
Shares: +209,100
Change %: +24%
Price: $10.00
Shares after: 1,098,318
Date: 29 Jun 2021
Ownership: See Footnote
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were acquired by RA Capital Management Healthcare Fund, L.P. (the "Fund") on June 29, 2021.

Footnote F2

RA Capital Management L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which the reporting person and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, The reporting person and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.